Scientific Committee - Allinky Biopharma

Members of the Scientific Committee and Founders of Allinky

Ignacio Torres, Prof. Dr. is a Research Professor and current director of the Instituto Cajal of CSIC (National Spanish Research Council). He received postdoctoral training at Tulane University working with Nobel Prize Andrew Schally and at Yale University with Fred Naftolin. His work is oriented to develop new therapeutic approaches for neurodegenerative diseases based on an understanding of IGF-I neuroprotective pathways. He has published over 100 research articles in international journals and invited to deliver lectures at prestigious institutions of more than 20 countries.

Juan José Gómez Reino, MD. Ph.D. Prof. is based in the Hospital Clinico Universitario at the Universidad de Santiago de Compostela (Spain) as Head of the Rheumatology Department. He was formerly Chief of the Department of Research and Section of Rheumatology at Hospital Doce de Octubre in Madrid (Spain). Professor Gómez-Reino completed his medical and doctor of philosophy degrees at the University of Madrid, Spain and his postgraduate training in internal medicine and rheumatology at the New York State University, Stony Brook (USA). The main focus of Professor Gomez-Reino’s clinical research is RA and AS treatment, and his experimental research is in the genetics of complex diseases, the effect of neuropeptides on chondrocyte function, and arthritis in animal models and gene “knockout” mice.  He has authored or co-authored original articles and papers on topics such as rheumatoid arthritis, spondyloarthritis and other rheumatology-specific disorders.

Juan Jesús Pérez, Ph.D. Prof. Full Professor of Physical Chemistry at the Department of Chemical Engineering at the Universitat Politecnica de Catalunya (Spain) since 1984. He has served as Senior Researcher in Molecular Research Institute of Palo Alto, California, between 1991 and 1993, Visiting Scientist at the IBM Laboratories in Kingston, New York, between 1987 and 1988, and visitor researcher at the University of Manchester's Institute of Science and Technology (UMIST) and the Max-Planck Institut fur Physik in Munich in 1983. In 1999 he received the Research Award of the INQUIFARMA Foundation for the discovery of new therapeutic agents for the treatment of psoriasis. At the present he is the General Secretary of awarding body of the QUEST quality label for engineering education.

Angel Messeguer, Dr. Prof. obtained his Ph.D. degree in Organic Chemistry at the University of Barcelona in 1974. In 1975 he joined the CSIC staff as Research Scientist. During the 1978-1979 he stayed as Fulbright postdoctoral fellow at the University of Cornell working with Prof. W.S. Bowers. In 1985 has was promoted to Research Associate at CSIC and in 1991 to Professor of Research. Currently he is head of the Bioorganic Research Group at the Instituto de Química Avanzada de Cataluña of CSIC (National Research Council) and its Director since 2005. He was President of the Catalan Society of Chemistry from 2002 to 2008. His major research interests have been focused on bioactive organic compounds and in the application of the modern Medicinal Chemistry methodology to the identification of hits relevant to pharmaceutical targets and their further chemical optimization to lead compounds. He has published 170 scientific articles, is co-inventor of 22 patent applications and supervisor of 23 Ph.D. theses.

Balbino Alarcón, Dr. Prof. is Professor of Research of the National Research Council of Spain (CSIC) working at the Centro de Biología Molecular Severo Ochoa as Head of the laboratory of TCR signal transduction since 1992. He obtained his Ph.D. degree with honorific mention in biochemistry at the University Autónoma of Madrid (1985) and held a postdoctoral research position at the Dana-Farber Cancer Institute (Harvard University) in Boston from 1985 to 1990 in the laboratory of Dr. Cox Terhorst. His research activities have focused since 1985 on the characterization of the earliest mechanisms of signal transduction by the T cell antigen receptor (TCR) and the identification of direct cytoplasmic effectors and modulators of the TCR that represent attractive molecular targets for the treatment of autoimmune diseases and cancer. Balbino Alarcón is member of EMBO since 2000 and was awarded the “Hoechst Marion Roussel” and “Carmen and Severo Ochoa” prizes in 1998 and 2002, respectively.